During the fiscal 2011 first quarter, the company plans to launch a new product, the InSpectra(TM) StO2 Spot Check, in Europe and the Middle East and to file for marketing clearance of the product in the United States under the U.S. Food and Drug Administration's Premarket Notification, or 510(k), process. "This handheld device leverages our StO2 measurement technology and enables clinicians to quickly and cost-effectively identify at-risk patients, who can then be continuously monitored with our InSpectra StO2 Tissue Oxygenation Monitor," said Penn.Penn said that the clinical and economic evidence for wider adoption of StO2 monitoring is compelling and growing. "Multiple clinical studies demonstrate that patients with low StO2 are at risk of poor outcomes and that measurement of StO2 identifies problems that other vital signs do not," said Penn. "Additionally, recent research suggests that using StO2 to guide patient treatment results in improved outcomes as well as economic benefits in the form of shortened length-of-stays in the ICU and hospital."
Hutchinson Technology Reports Fourth Quarter Loss On Reduced Volume
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.